A Boston biotech investment firm led by Bihua Chen that invests in private and public life sciences companies and is a frequent name in crossover rounds. Its website could not be reached at the time of research.
Cormorant Asset Management is a Boston-based life sciences investor that, according to the task hint, participates in private financings and public offerings of biotechnology companies, including oncology developers. At the time of research the domain cormorantcapital.com redirected to a GoDaddy 'for sale' parking page, an alternative (cormorantasset.com) did not resolve, and no Wikipedia article exists, so the firm's own description, founding year and portfolio could not be confirmed from a primary source.
| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| BridgeBio Oncology Therapeutics South San Francisco, CA, US | Public | biotech | Non-small-cell lung cancerColorectal cancerHER2-positive breast cancerHR-positive / HER2-negative breast cancer | IPO 2025, $382M |
| Stablix New York, NY, US | Startup | biotech | Series A 2021, $63M | |
| Tango Therapeutics Boston, MA, US | Public | biotech | Pancreatic ductal adenocarcinomaNon-small-cell lung cancerGlioma & glioblastoma | IPO 2021, $353M |
Shares Stablix and the tag vc.
Shares Tango Therapeutics and the tag vc.
Shares Tango Therapeutics and the tag vc.
Shares Tango Therapeutics and the tag vc.
Shares Tango Therapeutics and the tag vc.
Shares Tango Therapeutics and the tag vc.
Shares Tango Therapeutics and the tag vc.
Shares Tango Therapeutics and the tag vc.